Effectiveness of Prophylactic Antibiotics Therapy in Laparoscopic Cholecystectomy on Infection Rate
Prospective Randomized Control Study of Clinical Effectiveness of Prophylactic Antibiotics Therapy in Laparoscopic Cholecystectomy on Infection Rate
529 patients performed elective LCC at Chonbuk National University Hospital between April 2014 and August 2015. Total 509 patients were enrolled by inclusion criteria.
They were randomized studied by comparing with antibiotic group (n=249, AG, cefotetan 1g, 1 dose/prophylactic) and non-antibiotic group (n=260, NAG) by table of random numbers. The clinical variables were pre and post-operatively blood tests enclude WBC, ESR, CRP, body temperatures, symptoms and imaging of chest x-ray to evaluate the infections.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
patients who have diagnosed -cholecystitis with / without GB stone, GB polyp
Exclusion Criteria:
- Suspected cholangitis and GB cancer
- CBD stone history
- Preoperative administration of antibiotics within 7days.
- Suspected pregnancy
- Open conversion.
- Patients refuse this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Antibiotic treatment group
They were Antibiotic treatment group (AG, cefotetan 1g, 1 dose/prophylactic) before surgery.
|
Cefotetan (as Disodium) 1 GM Injection before surgery
Other Names:
|
|
NO_INTERVENTION: Non-antibiotic treatment group
They were Non-antibiotics treatment such as cefotetan 1g before surgery.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
surgical complication
Time Frame: 30days
|
surgical site infection
|
30days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Jae Do Yang, Chonkbuk national university
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ChonbukNUH
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cholecystitis
-
NCT07616713CompletedAcute Cholecystitis | Acute Cholecystitis With Obstruction
-
NCT01942356CompletedAcute Cholecystitis | Chronic Cholecystitis
-
NCT04596306Completed
-
NCT00323648CompletedUncomplicated Acute Cholecystitis
-
NCT05272007Recruiting
-
NCT06873295Completed
-
NCT06601855CompletedAcute Cholecystitis
-
NCT02057679Completed
Clinical Trials on Cefotetan
-
NCT00186082CompletedPregnancy Complications, Infectious
-
NCT01220661Completed
-
NCT07318584Not yet recruitingE Coli Infection | ESBL Producing E.Coli
-
NCT02099240Terminated